Ibogaine for PTSD

4 papers and 2 clinical trials exploring ibogaine as a treatment for ptsd.

CompoundIndole Alkaloid

Ibogaine

A unique indole alkaloid with complex pharmacology, investigated primarily for its capacity to interrupt substance use disorders and withdrawal.

Full Ibogaine profile
Indication354 million people suffering from PTSD globally.

PTSD

Posttraumatic stress disorder (PTSD) is a significant mental health challenge affecting over 354 million individuals globally. Psychedelics, particularly MDMA and psilocybin, are emerging as promising therapeutic options, offering new avenues for treatment through innovative psychotherapeutic interventions.

Full PTSD profile

Academic Research

4 papers
Paywallindividual

Mystical experiences during magnesium-Ibogaine are associated with improvements in PTSD symptoms in veterans

This secondary analysis of an open-label study (n=30) of male Veterans with traumatic brain injury found that greater intensity of mystical experiences during magnesium-ibogaine treatment was associated with larger reductions in PTSD severity both immediately and one month post-treatment, as well as greater reductions in peak alpha frequency at one month.

Published
Journal
Journal of Affective Disorders
Authors
Brown, R. E., Lissemore, J. I., Shinozuka, K. F., Coetzee, J. P., Faerman, A., Olash, C. A., Geoly, A. D., Buchanan, D. M., Cherian, K. N., Chaiken, A., Shamma, A., Sridhar, M., Hunegnaw, S. A., Johnson, N. D., Rolle, C. E., Adamson, M. M., Williams, N. R.
Open Accessindividual

Psychedelic treatment for co-occurring alcohol misuse and post-traumatic stress symptoms among United States Special Operations Forces Veterans

In a retrospective survey of 27 US Special Operations Forces veterans who completed a psychedelic treatment programme in Mexico, self‑reported alcohol misuse and post‑traumatic stress symptoms showed marked reductions with very large effect sizes (d≈–2.4 to –2.8) and 85% reduced drinking to non‑risky levels, while psychological flexibility increased. The uncontrolled, retrospective design limits causal inference, and the authors call for rigorous longitudinal trials to determine whether psychedelic‑assisted therapy is effective in this population.

Published
Journal
Journal of Psychedelic Studies
Authors
Averill, L. A., Davis, A. K., Mangini, P.
Open Accessindividual

Long-term Follow-Up Outcomes of MDMA-assisted Psychotherapy for Treatment of PTSD: A Longitudinal Pooled Analysis of Six Phase 2 Trials

Pooled analysis of six phase 2 trials found that two to three MDMA‑assisted psychotherapy sessions produced large reductions in PTSD severity at 1–2 months (LS mean change −44.8; Cohen’s d = 1.58) with further small but significant improvement at least 12 months post‑treatment (LS mean change −5.2; d = 0.23). The proportion no longer meeting PTSD criteria rose from 56% at treatment exit to 67% at long‑term follow‑up, most participants reported lasting benefits (improved relationships and well‑being) and only a minority reported harms; phase 3 trials are underway to confirm these results.

Published
Journal
Psychopharmacology
Authors
Doblin, R., Emerson, A., Feduccia, A. A., Hamilton, S., Jerome, L., Mithoefer, M. C., Wang, J. B., Yazar-Klosinski, B.

Clinical Trials

2 trials

Explore further

Search all Ibogaine papers Search all PTSD trials Full Ibogaine profile Full PTSD profile